AI Drug Discovery Company LabGenius
Joint Research on Multi-Antibody Cancer Targets

On June 18, LG Chem announced that it has signed a joint research and license option agreement with UK-based LabGenius Therapeutics to discover multi-antibody cancer drug candidates.


LG Chem Partners with UK LabGenius to Discover Multi-Antibody Cancer Drug Candidates View original image

Under this agreement, LG Chem will pay LabGenius an upfront payment and research funding, among other fees. Going forward, the two companies will decide whether to proceed with subsequent development and exercise the license option based on the jointly agreed evaluation criteria for research outcomes.


LabGenius is an AI-driven biotech company that has independently developed and operates EVA™, a platform that optimizes therapeutic antibodies by combining machine learning with high-throughput experimentation (HTE) technologies and equipment. Based on the establishment of a fully autonomous laboratory, the company has secured Series B funding (with LG Corp. as a participant) and has entered into strategic partnerships with global big pharma companies.


LG Chem explained that, by employing a repetitive research cycle in which AI designs, produces, and robotically tests a large number of antibodies, and then analyzes the results through machine learning before applying this data to the next round of antibody design, it can discover more stable and optimized antibodies at a faster pace.


LG Chem’s strategy is to halve the time required for antibody drug candidate discovery—which typically takes more than five years due to the complexity of protein structures from target validation to lead optimization—thereby moving joint research candidates into the clinical phase (preclinical stage) more quickly.


Jinun So, Head of Life Sciences and R&D at LG Chem, stated, “LabGenius is an AI drug development company equipped with the systems and capabilities to rapidly conduct candidate screening and early evaluation, based on an automated wet lab and a computing dry lab in a cyclical structure. In the field of cancer therapeutics, where there is significant unmet medical need, we aim to swiftly identify new drug candidates that are more effective and less toxic than existing compounds.”


James Field, CEO of LabGenius Therapeutics, commented, “This partnership is an important opportunity to demonstrate the innovative nature of our proprietary drug discovery platform. Through highly optimized multi-antibody design and production, we will support the acceleration of LG Chem’s new drug development.”



Meanwhile, LG Chem is sharpening its competitive edge in the global AI-driven drug discovery race. The company has developed an integrated AI platform for the entire drug development cycle, called MediX, which is being used for optimal target discovery, drug candidate efficacy prediction and selection, and is planned to be further expanded to clinical development, manufacturing, and processing. At the same time, LG Chem is pursuing maximized success rates and efficiency in drug discovery through open innovation. The company is building a genomic analysis model with LG AI Research and conducting joint research with AI drug discovery company Galux to design new structures of lead anti-cancer proteins.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing